Isradipine

TargetMol
Product Code: TAR-T0957
Supplier: TargetMol
CodeSizePrice
TAR-T0957-5mg5mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0957-1mL1 mL * 10 mM (in DMSO)£111.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0957-10mg10mg£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0957-25mg25mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0957-50mg50mg£201.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0957-100mg100mg£287.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T0957-500mg500mg£607.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Isradipine is a dihydropyridine calcium channel blockers with antihypertensive and vasodilator activities. Isradipine blocks the calcium entry through the calcium ion channels of coronary and peripheral vascular smooth muscle, thereby dilating coronary arteries and peripheral arterioles. This increases oxygen delivery due to an increased blood flow and reduces oxygen requirements due to decreasing in total peripheral resistance.
CAS:
75695-93-1
Formula:
C19H21N3O5
Molecular Weight:
371.393
Pathway:
Membrane transporter/Ion channel; Autophagy; Metabolism
Purity:
0.9984
SMILES:
COC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OC(C)C
Target:
Calcium Channel; Autophagy

References

1. N??ez-Vergara LJ, et al. Gen Pharmacol. 1998 Jan;30(1):85-7. 2. Barhwal K, et al. Neurobiol Dis, 2009, 34(2), 230-244. 3. Fadda F, et al. Alcohol Clin Exp Res, 1992, 16(3), 449-452. 4. Levy BI, et al. Circulation, 1994, 90(6), 3024-3033. 5. Kuzmin A, et al. Pharmacol Biochem Behav, 1992, 41(3), 497-500.